BioMed Research International / 2013 / Article / Tab 1 / Review Article
The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis Table 1 Characteristics of the 13 studies included in the meta-analysis.
Study Publication year No. of NHL patients Study design Stage Functional imaging PET timing Survival data PET (+) as prognostic factor for survival Methodology score (%) Zinzani et al. [7 ] 2011 DLBCL (
) PMLBCL (
) Retrospective Stage II–IV PET I-PET OS & PFS Significant 65.79% Yoo et al. [8 ] 2011 DLBCL (
) Retrospective Stage I–IV PET/CT I-PET, final PET OS & PFS Undetermined 78.95% Yang et al. [9 ] 2011 DLBCL (
) Prospective Stage I–IV PET/CT I-PET OS & PFS Significant 89.47% Trotman et al. [10 ] 2011 FL (
) Prospective Stage III-IV PET/CT F-PET OS & PFS Significant 71.05% Safar et al. [11 ] 2012 DLBCL (
) Retrospective Stage III-IV PET I-PET OS & PFS Significant 71.05% Pregno et al. [12 ] 2012 DLBCL (
) Retrospective Stage I–IV PET/CT I-PET, F-PET PFS Undetermined 78.95% Le Dortz et al. [13 ] 2010 FL (
) Retrospective Stage I–IV PET/CT F-PET PFS Significant 71.05% Han et al. [14 ] 2009 DLBCL (
)
) Retrospective Stage I–IV PET I-PET, F-PET OS & PFS Undetermined 63.16% Cox et al. [15 ] 2012 DLBCL (
) PMLBCL (
) Prospective Stage I–IV PET I-PET OS & PFS Undetermined 76.68% Cashen et al. [16 ] 2011 DLBCL (
) Prospective Stage III-IV PET/CT I-PET, F-PET OS & PFS Significant 71.05% Mato et al. [17 ] 2012 MCL (
) Retrospective N/A PET/CT I-PET, F-PET OS & PFS F-PET: significant I-PET: undetermined 50.00% Lanic et al. [18 ] 2012 DLBCL (
) Retrospective N/A PET I-PET OS & PFS Significant 71.05% Dupuis et al. [19 ] 2012 FL (
) Prospective Grade 1 to 3A PET I-PET, F-PET OS & PFS Significant (OS of I-PET: undetermined) 84.21%
